Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.35 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699689 | 1.00 | RAF1 (0.35) | RAF1ACACBBRAF | |
| SCHEMBL19689859 | 1.00 | RAF1 (0.35) | RAF1ACACBBRAF | |
| SCHEMBL19689703 | 0.92 | RAF1 (0.33) | RAF1ACACB | |
| SCHEMBL19689704 | 0.92 | RAF1 (0.33) | RAF1ACACB | |
| SCHEMBL17768082 | 0.90 | RAF1 (0.41) | RAF1BRAF | |
| SCHEMBL17768080 | 0.90 | RAF1 (0.41) | RAF1BRAF | |
| SCHEMBL17778811 | 0.85 | RAF1 (0.32) | RAF1ACACBBRAF | |
| SCHEMBL17768184 | 0.85 | RAF1 (0.32) | RAF1ACACBBRAF | |
| SCHEMBL17768186 | 0.85 | RAF1 (0.32) | RAF1ACACBBRAF | |
| SCHEMBL19689721 | 0.82 | RAF1 (0.37) | RAF1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RAF1 2078/4885ACACB 318/4885BRAF 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.